Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
78 hedge funds and large institutions have $18.6M invested in Oncternal Therapeutics, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 22 increasing their positions, 26 reducing their positions, and 17 closing their positions.
5% less funds holding
Funds holding: 82 → 78 (-4)
15% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 26
24% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 17
39% less capital invested
Capital invested by funds: $30.5M → $18.6M (-$11.9M)
68% less call options, than puts
Call options by funds: $60K | Put options by funds: $189K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$766K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$350K |
| 3 |
Renaissance Technologies
New York
|
+$304K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$183K |
| 5 |
Two Sigma Advisers
New York
|
+$154K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$657K |
| 2 |
ECM
ExodusPoint Capital Management
New York
|
-$310K |
| 3 |
ACM
ACT Capital Management
Wayne,
Pennsylvania
|
-$246K |
| 4 |
Morgan Stanley
New York
|
-$223K |
| 5 |
BlackRock
New York
|
-$148K |
ONCT Hedge Fund Activity: Q1 2022 in Review
78 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q1 2022, worth a combined $18.6M — down 39% from $30.5M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of ONCT and 13 opened new positions — a net loss of 4 holders — while 26 trimmed existing stakes and 22 added.
The largest buyer was Healthcare of Ontario Pension Plan (HOOPP) Trust Fund, opening a new position worth an estimated $766K. The largest seller was Parkman Healthcare Partners, exiting entirely with an estimated $657K sold.
- 78 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q1 2022, down from 82 in Q4 2021.
- Funds reported $18.6M of Oncternal Therapeutics, Inc. Common Stock stock for Q1 2022, down 39% quarter-over-quarter.
- 13 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q1 2022 and 17 closed out, a net change of -4 holders.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q1 2022 was Healthcare of Ontario Pension Plan (HOOPP) Trust Fund, an estimated $766K added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q1 2022 was Parkman Healthcare Partners, an estimated $657K sold.
Based on aggregated 13F filings for Q1 2022.